Piramal Pharma gains on launch of zinc injection in US

Shares of Piramal Pharma Limited traded over a percent higher at Rs 140 in the early trade on January 17 after its Piramal Critical Care (PCC) division announced the launch of zinc sulfate injection in the US.

“The launch will enable PCC further to expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio,” the company said in an exchange filing on January 16.

At 9:25 am, the scrip was trading at Rs 139 on the National Stock Exchange, up 0.5 percent from the previous close . The stock has gained nearly 24 percent in the past year.

Follow our market blog for all the live action

Zinc sulfate is a trace element indicated in adult and pediatric patients as a source of zinc for nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

The introduction of Zinc Sulfate for Injection, USP 10mg/10ml marks the latest addition to Piramal Critical Care’s series of recent product launches in the generic injectables market.

In 2023, the company also unveiled Pantoprazole Sodium for Injection, USP, and Doxycycline for Injection, USP, expanding its diverse portfolio of critical care products.

“The introduction of Zinc Sulfate Injection expands our US portfolio of injectable products, complementing our inhaled anaesthesia offerings,” Piramal Global Pharma CEO Peter DeYoung said.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.